Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2011-02-28 Capital/Financing Update
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Appendix 3B 10 pages 498.0KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX listing rules (Rule 2.7, 3.10.3, 3.10.4, 3.10.5). It details the issuance of convertible notes, the number and class of securities issued, terms of the securities, and application for quotation of additional securities on the ASX. The document is a formal announcement of a new securities issue and application for quotation, consistent with the Appendix 3B form used in Australian securities regulation for new issue announcements. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is a capital raising and securities issuance announcement.
2011-02-28 English
Change of Director`s Interest Notice 5 pages 625.5KB
Director's Dealing Classification · 100% confidence The document is an Appendix 3Y form, which is a Change of Director's Interest Notice filed under ASX listing rules. It details the transfer and reorganization of shares held by a director, Dr Michael Monsour, including specifics of shareholdings before and after the change, dates, and consideration. The document is a regulatory disclosure about insider share transactions by a company director. It does not contain financial statements, earnings data, or management discussion. It is not an announcement of a report, nor a full report itself. This type of document fits the category of Director's Dealing (DIRS), which covers personal share transactions by company directors and executives (insider trades). The document length and content confirm it is a full notice, not a brief announcement or certification. Therefore, the correct classification is DIRS with high confidence.
2011-02-27 English
Change in substantial holding 4 pages 150.9KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 under the Corporations Act 2001, titled 'Notice of change of interests of substantial holder.' It details changes in voting power and relevant interests of a substantial shareholder, including dates, share classes, and associated entities. The form is regulatory in nature, reporting changes in shareholding interests rather than financial performance, management changes, or other corporate events. It is not an annual report, earnings release, or any form of financial statement. It is a notification of substantial shareholding changes, which corresponds to the category 'Major Shareholding Notification' (MRQ). The document length and content confirm it is the actual notice, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2011-02-27 English
Half Yearly Report and Accounts 22 pages 661.3KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4D Half Year Report' for the 6 months ended December 2010, which indicates it is a half-year financial report. It contains detailed financial results, including revenue, net loss, net tangible asset backing per share, and a directors' report. It also discusses operational activities, capital raising, and changes in directors during the half-year period. The document is approximately 15,000 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or certification. The presence of an audit review statement and detailed financial and operational information confirms it is a comprehensive interim report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2011
2011-02-24 English
Response to ASX Price Query 5 pages 229.1KB
Regulatory Filings Classification · 95% confidence The document is a response letter from CBio Limited to the ASX Limited regarding a price query about a recent change in the company's share price and trading volume. It addresses specific questions from the ASX about undisclosed information, potential profit/loss changes, and compliance with listing rules. The content is a regulatory communication related to stock price movements and compliance, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but is a formal regulatory response to a market query. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2011-02-21 English
Repayment of Convertible Note 2 pages 168.7KB
Capital/Financing Update Classification · 95% confidence The document is a formal announcement addressed to the ASX Limited Company Announcements Office, dated 18 February 2011. It informs about the repayment of a convertible note by CBio Limited, including details of the remaining convertible notes on issue. The content focuses on a specific financing event related to convertible notes, which is a capital structure update. There is no indication of financial statements, audit information, or detailed financial results. The document length is 3522 characters, which is relatively short and consistent with an announcement rather than a full report. The key phrase 'repayment of convertible note' and the detailed note information align with a Capital/Financing Update. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2011-02-17 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.